Atlas Trials

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Clinical trial NCT06124001 · UNKNOWN

Trial details

NCT number
NCT06124001
Sponsor
CNBG-Virogin Biotech (Shanghai) Ltd.
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Primary Hepatocellular Carcinoma
Start date
2023-11-30
Primary completion
2025-12-30
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.